Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041990 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
A Phase 2 study of Chronic Myelogenous Leukemia, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT00041990 is a Phase 2 study of Chronic Myelogenous Leukemia that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 40 participants, below the 281-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT00041990, a Phase 2 study of Chronic Myelogenous Leukemia, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Conditions Studied
Interventions
- DRUG decitabine (5-aza-2'deoxycytidine)
Study Locations (8)
California
- City of Hope Medical Center - Duarte
- Scripps Clinic - Escondido
- USC/Norris Cancer Center - Los Angeles
Minnesota
- Metro-Minnesota CCOP - Saint Louis Park
New York
- New York Medical College - Valhalla
South Carolina
- Liberty Hematology/Oncology - Columbia
Texas
- University of Texas MD Anderson Cancer Center - Houston
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041990
The ClinicalTrials.gov registry entry for NCT00041990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (86% lower). The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which decitabine (5-aza-2'deoxycytidine) is the first listed.
NCT00041990 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT00041990 about?
NCT00041990 is a clinical study titled "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)". To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
What is the current status of trial NCT00041990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-07.
What conditions does trial NCT00041990 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00041990?
The interventions under investigation include: decitabine (5-aza-2'deoxycytidine) (DRUG).
Who is sponsoring clinical trial NCT00041990?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00041990 being conducted?
This trial has 8 study locations across California, Minnesota, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
ACTIVE NOT RECRUITING · Phase 2
-
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
ACTIVE NOT RECRUITING · Phase 2
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.